Clinical trial
Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00090090 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00090090 |
|---|---|
| Title | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Intervention type | Drug |
| Interventions | Elsamitrucin |
| Enrollment | 114 |
| Start date | Apr 1, 2004 |
| Completion | Oct 1, 2006 |
| First posted | Aug 25, 2004 |
| Last update posted | Jan 15, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: